Direct molecular diagnosis of friedreich ataxia
CA 2248016 C · Owner: Montermini, Laura · Inventors: Koenig, Michael; Campuzano, Victoria; Molto, Maria
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates generally to methods for the diagnosis and therapeutic treatment of Friedreich Ataxia. Friedreich ataxia (FRDA) is an autosomal recessive, degenerative disease that involves the central and peripheral nervous system and the heart. A gene, X25 was identified in the critical , region for the FRDA locus on chromosome 9q13. The gene encodes a 210 amino acid protein, frataxin, that has homologues in distant species such as C. elegans and yeast. A few FRDA patients have been found to have point mutations in X25, but the vast majority are homozygous for a variable unstable GAA , trinucleotide expansion in the first X25 intron. Mature X25 mRNA was severely reduced in …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 4, 1997 and granted May 10, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 4, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 4, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.